Shima Y - Search Results

1

Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab.

Tanaka T, Kuwahara Y, Shima Y, Hirano T, Kawai M, Ogawa M, Arimitsu J, Hagihara K, Narazaki M, Ogata A, Kawase I, Kishimoto T. Tanaka T, et al. Among authors: shima y. Arthritis Rheum. 2009 Dec 15;61(12):1762-4. doi: 10.1002/art.24899. Arthritis Rheum. 2009. PMID: 19950316 Free article. No abstract available.

2

Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis.

Shima Y, Nishimoto N, Ogata A, Fujii Y, Yoshizaki K, Kishimoto T. Shima Y, et al. Blood. 1995 Feb 1;85(3):757-64. Blood. 1995. PMID: 7530506 Free article.

3

Serum interleukin 6 as a predicator of the therapeutic effect and adverse reactions after transcatheter arterial embolization.

Yamazaki H, Nishimoto N, Oi H, Matsushita M, Ogata A, Shima Y, Inoue T, Tang JT, Yoshizaki K, Kishimoto T, et al. Yamazaki H, et al. Among authors: shima y. Cytokine. 1995 Feb;7(2):191-5. doi: 10.1006/cyto.1995.1026. Cytokine. 1995. PMID: 7780039

4

Gp130 in human myeloma/plasmacytoma.

Tani Y, Nishimoto N, Ogata A, Shima Y, Yoshizaki K, Kishimoto T. Tani Y, et al. Among authors: shima y. Curr Top Microbiol Immunol. 1995;194:229-33. doi: 10.1007/978-3-642-79275-5_27. Curr Top Microbiol Immunol. 1995. PMID: 7895494 No abstract available.

5

Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction.

Ogata A, Nishimoto N, Shima Y, Yoshizaki K, Kishimoto T. Ogata A, et al. Among authors: shima y. Blood. 1994 Nov 1;84(9):3040-6. Blood. 1994. PMID: 7949175 Free article.

6

[Interleukin-6].

Nishimoto N, Ogata A, Shima Y, Yoshizaki K. Nishimoto N, et al. Among authors: shima y. Gan To Kagaku Ryoho. 1994 Aug;21(10):1707-16. Gan To Kagaku Ryoho. 1994. PMID: 8060152 Review. Japanese.

7

Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130.

Nishimoto N, Ogata A, Shima Y, Tani Y, Ogawa H, Nakagawa M, Sugiyama H, Yoshizaki K, Kishimoto T. Nishimoto N, et al. Among authors: shima y. J Exp Med. 1994 Apr 1;179(4):1343-7. doi: 10.1084/jem.179.4.1343. J Exp Med. 1994. PMID: 8145046 Free PMC article.

8

Fas antigen/APO-1 (CD95) expression on myeloma cells.

Shima Y, Nishimoto N, Yoshizaki K, Kishimoto T. Shima Y, et al. Leuk Lymphoma. 1996 Nov;23(5-6):521-31. doi: 10.3109/10428199609054860. Leuk Lymphoma. 1996. PMID: 9031082 Review.

9

Myeloma biology and therapy. Present status and future developments.

Nishimoto N, Shima Y, Yoshizaki K, Kishimoto T. Nishimoto N, et al. Among authors: shima y. Hematol Oncol Clin North Am. 1997 Feb;11(1):159-72. doi: 10.1016/s0889-8588(05)70421-4. Hematol Oncol Clin North Am. 1997. PMID: 9081210 Review.

10

Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.

Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, Kishimoto T, Yoshizaki K. Nishimoto N, et al. Among authors: shima y. Blood. 2000 Jan 1;95(1):56-61. Blood. 2000. PMID: 10607684 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

811 results

Search Page

Filters